Denver Investment Advisors’s Emergent Biosolutions EBS Stock Holding History

Denver Investment Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-6,996	Closed	-$280K	–	478
2015 Q4	$280K	Sell	6,996 -794	-10%	-$27.7K	0.01%	404
2015 Q3	$222K	Sell	7,790 -268	-3%	-$8.83K	0.01%	442
2015 Q2	$266K	Sell	8,058 -2,201	-21%	-$68.2K	0.01%	436
2015 Q1	$295K	Sell	10,259 -217	-2%	-$6.22K	0.01%	483
2014 Q4	$285K	Buy	10,476 +44	+0.4%	+$1.05K	0.01%	475
2014 Q3	$222K	Buy	+10,432	New	+$239K	0.01%	511

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Denver Investment Advisors's EBS Position: Q1 2016 in Review

Denver Investment Advisors sold out of Emergent Biosolutions (EBS) in Q1 2016, closing a stake of 6,996 shares — an estimated $280K sold.

Denver Investment Advisors first reported a position in EBS in Q3 2014 and held it in 6 quarters. The position peaked at $295K in Q1 2015. 214 funds tracked by Wall St. Rank hold EBS as of Q1 2016.

Denver Investment Advisors reported no remaining Emergent Biosolutions position as of Q1 2016 after selling out during the quarter.
Denver Investment Advisors sold 6,996 Emergent Biosolutions shares in Q1 2016, an estimated $280K.
Denver Investment Advisors first reported a position in Emergent Biosolutions in Q3 2014 and held it in 6 quarters.
Denver Investment Advisors's Emergent Biosolutions position peaked at $295K in Q1 2015.
214 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2016.

Based on Denver Investment Advisors's 13F filing for Q1 2016, filed 12 May 2016.